Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years
Anne M. Hause, David K. Shay, Nicola P. Klein, et al.
PEDIATRICS (2022) Vol. 150, Iss. 2
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 167
Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years
Atsuyuki Watanabe, Ryoma Kani, Masao Iwagami, et al.
JAMA Pediatrics (2023) Vol. 177, Iss. 4, pp. 384-384
Open Access | Times Cited: 60
Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis
Vanessa Piechotta, Waldemar Siemens, Iris Thielemann, et al.
The Lancet Child & Adolescent Health (2023) Vol. 7, Iss. 6, pp. 379-391
Open Access | Times Cited: 51
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
Katherine E. Fleming-Dutra, Megan Wallace, Danielle Moulia, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 26, pp. 859-868
Open Access | Times Cited: 65
SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era
Haifa Khemiri, Kaouther Ayouni, Henda Triki, et al.
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 64
Batch‐dependent safety of the BNT162b2 mRNA COVID‐19 vaccine
Max Schmeling, Vibeke Manniche, Peter Riis Hansen
European Journal of Clinical Investigation (2023) Vol. 53, Iss. 8
Open Access | Times Cited: 29
Pfizer-BioNTech COVID-19 vaccine safe in children

Reactions Weekly (2022) Vol. 1908, Iss. 1, pp. 11-11
Closed Access | Times Cited: 34
Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysis
Peng Gao, Liangyu Kang, Jue Liu, et al.
World Journal of Pediatrics (2023) Vol. 19, Iss. 11, pp. 1041-1054
Open Access | Times Cited: 21
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic
Lauri E. Markowitz, Robert Hopkins, Karen R. Broder, et al.
Vaccine (2024) Vol. 42, pp. 125549-125549
Open Access | Times Cited: 7
Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022
Anne M. Hause, James Baggs, Paige Marquez, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 33, pp. 1047-1051
Open Access | Times Cited: 26
A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2
Shanhong Mao, Shiyou Li, Yuxin Zhang, et al.
Nano Today (2022) Vol. 48, pp. 101730-101730
Open Access | Times Cited: 26
COVID-19 Vaccines and Myocarditis: An Overview of Current Evidence
Altijana Hromić‐Jahjefendić, Abas Sezer, Alaa A. A. Aljabali, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1469-1469
Open Access | Times Cited: 15
Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance
Helena C. Maltezou, Sophia Hatziantoniou, Kalliopi Theodoridou, et al.
Vaccine (2023) Vol. 41, Iss. 14, pp. 2382-2386
Open Access | Times Cited: 13
Real-Time Pharmacovigilance: Transforming Population-Based Monitoring of Post-Approval Vaccine Safety Through Rapid Cycle Analysis (RCA)—A Review of the Published Literature
Sampada Gandhi, Michelle R. Iannacone, Alyssa C. Leapley, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 1, pp. 80-80
Open Access
COVID-19 vaccination for children aged 5–11 years
Shamez Ladhani
The Lancet (2022) Vol. 400, Iss. 10346, pp. 74-76
Open Access | Times Cited: 19
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study
А. И. Тухватулин, Inna V. Dolzhikova, Alina S. Dzharullaeva, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Emerging and re-emerging pediatric viral diseases: a continuing global challenge
Seth A. Hoffman, Yvonne Maldonado
Pediatric Research (2023) Vol. 95, Iss. 2, pp. 480-487
Open Access | Times Cited: 9
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink
Tat’Yana A. Kenigsberg, Kayla E. Hanson, Nicola P. Klein, et al.
Vaccine (2023) Vol. 41, Iss. 32, pp. 4658-4665
Open Access | Times Cited: 8
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks
Abdolreza Esmaeilzadeh, Armin Jahani Maleki, Amirhosein Moradi, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 10, pp. 1377-1394
Closed Access | Times Cited: 13
Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study
Alessia Zinzi, Mario Gaio, Valerio Liguori, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 401-401
Open Access | Times Cited: 7
Factors associated with childhood non-vaccination against COVID-19 in Canada: A national survey analysis
David Guan, Sailly Dave, Marwa Ebrahim, et al.
Vaccine X (2024) Vol. 18, pp. 100478-100478
Open Access | Times Cited: 2
Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5–11 years: a phase 2/3, randomized, active-controlled study
Rino Suzuki, Miharu Suda, Katsuyasu Ishida, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Myocarditis and Pericarditis are Temporally Associated with BNT162b2 COVID-19 Vaccine in Adolescents: A Systematic Review and Meta-analysis
Yongyeon Choi, Jue Seong Lee, Young June Choe, et al.
Pediatric Cardiology (2024)
Closed Access | Times Cited: 2
mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study
Phyumar Soe, Otto G. Vanderkooi, Manish Sadarangani, et al.
The Lancet Regional Health - Americas (2024) Vol. 40, pp. 100949-100949
Open Access | Times Cited: 2
A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID‐19 mRNA vaccination
Pierre‐Philippe Piché‐Renaud, Shaun K. Morris, Karina A. Top
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 3, pp. 967-981
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top